Samsung C&T and Samsung Electronics have entered into a strategic collaboration with GRAIL, Inc. to introduce GRAIL’s Galleri multi-cancer early detection (MCED) test to Asia, starting with South Korea and potentially expanding to Japan and Singapore. As part of this initiative, Samsung C&T and Samsung Electronics will make an equity investment of $110 million into GRAIL at $70.05 per share.
Under the agreement, Samsung C&T will take the lead in commercializing the Galleri test in South Korea, while GRAIL will perform testing at its North Carolina-based clinical laboratory. The partnership aims to make early cancer detection more accessible, leveraging GRAIL’s genomic expertise and Samsung’s extensive regional network.
Additionally, Samsung Electronics and GRAIL plan to explore broader strategic and operational collaborations, such as integrating Samsung’s AI-driven digital health platform with GRAIL’s genetic data and technologies. This collaboration reflects Samsung’s vision of using innovation and data-driven healthcare to improve quality of life and advance preventive medicine.
The definitive agreements are expected to be finalized in early 2026, with commercial operations launching soon after. Through this partnership, Samsung strengthens its presence in the life sciences sector and contributes to the global fight against cancer through advanced diagnostics.
Leave a comment